Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Assembly Biosciences Stock Soared Today

By Maxx Chatsko - Oct 16, 2019 at 3:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported promising updates for two important pipeline programs.

What happened

Shares of Assembly Biosciences (ASMB -2.35%) gained over 41% today after the company announced an update on its hepatitis B virus (HBV) programs. 

The first update, from a phase 2a study evaluating the lead drug candidate ABI-H0731, suggests that the pipeline asset is effective in reducing DNA and RNA signatures of the virus. The second update, from a phase 1b study of a next-generation drug candidate named ABI-H2158, suggests that the asset can reduce the activity of the virus after just 14 days. 

As of 3:53 p.m. EDT, the stock had settled to a 38.2% gain.

A businessman looking at his laptop while riding a cartoon rocket.

Image source: Getty Images.

So what

The two lead candidates of Assembly Biosciences belong to a class of drugs called core inhibitors. The compounds are intended to disrupt HBV replication and the pool of cccDNA -- a type of DNA required for certain viruses to replicate -- that is often permanently lodged in an individual's cells.

The biopharma announced that individuals treated with ABI-H0731 and nucleos(t)ide analogs (Nrtl) achieved a deeper decline in HBV DNA and RNA than those treated with Nrtl alone. The combination also led to steeper declines in the biomarkers thought to indicate the amount of cccDNA present in an individual's cells. 

The update for ABI-H2158 only mentioned that researchers observed "potent antiviral activity" from the drug candidate.

Now what

Assembly Biosciences provided updates from the ongoing clinical trials because each has been accepted into a late-breaking session of the American Association for the Study of Liver Diseases annual meeting on Nov. 11. Management intends to hold a conference call the same day to provide the information to investors, too. A market cap of just $330 million suggests Wall Street isn't too optimistic about the biopharma, but that could change depending on the details of the planned update. Investors will have to wait to find out.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Assembly Biosciences, Inc. Stock Quote
Assembly Biosciences, Inc.
$2.08 (-2.35%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.